These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26684327)

  • 21. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients.
    Gallone G; Armeni P; Verheye S; Agostoni P; Timmers L; Campo G; Ielasi A; Sgura F; Tarantini G; Rosseel L; Zivelonghi C; Leenders G; Stella P; Tebaldi M; Tespili M; D'Amico G; Baldetti L; Ponticelli F; Colombo A; Giannini F
    Eur Heart J Qual Care Clin Outcomes; 2020 Jan; 6(1):32-40. PubMed ID: 31124556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria.
    Kanters TA; Thio HB; Hakkaart L
    Br J Dermatol; 2018 Sep; 179(3):702-708. PubMed ID: 29476533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.
    Takeshima T; Sakai F; Wang X; Yamato K; Kojima Y; Zhang Y; Bennison C; Simons MJHG
    Pharmacoeconomics; 2024 Jul; 42(7):811-822. PubMed ID: 38771521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
    Ayyasamy L; Bagepally BS
    Clin Ther; 2023 May; 45(5):458-465. PubMed ID: 37087299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of stent-retriever thrombectomy in large vessel occlusion strokes of the anterior circulation: Analysis from the French societal perspective.
    Barral M; Armoiry X; Boudour S; Aulagner G; Schott AM; Turjman F; Gory B; Viprey M
    Rev Neurol (Paris); 2020 Mar; 176(3):180-188. PubMed ID: 31526554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
    Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
    J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
    Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
    Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
    Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
    Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany.
    Hofer F; Achelrod D; Stargardt T
    Appl Health Econ Health Policy; 2016 Dec; 14(6):691-701. PubMed ID: 27475635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
    Geitona M; Stamuli E; Giannakodimos S; Kimiskidis VK; Kountouris V; Charokopou M; Christou P
    J Med Econ; 2019 Apr; 22(4):359-364. PubMed ID: 30652931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
    Teti VP; Akdagli S; Most SP
    JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
    Gourzoulidis G; Koulentaki M; Koumarianou A; Samadas E; Androulakis N; Xynogalos S; Papakotoulas P; Boukovinas I; Karamouzis M; Souglakos J; Chotzagiannoglou V; Beletsi A; Kourlaba G
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):259-269. PubMed ID: 33900864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.